Early pharmaceutical evaluation of a crystalline and hygroscopic GABAB receptor agonist

References

• Palucki M, Higgins JD, Kwong E, Templeton AC. (2010). Strategies at the interface of drug discovery and development: Early optimization of the solid state phase and preclinical toxicology formulation for potential drug candidates. J Med Chem, 53:5897–5905.
   PubMed Web of Science ®Google Scholar
• Qin X, Frech P. (2001). Liquid chromatography/mass spectrometry (LC/MS) identification of photooxidative degradates of crystalline and amorphous MK-912. J Pharm Sci, 90:833–844.
   PubMed Web of Science ®Google Scholar
• Shah RB, Bryant A, Collier J, Habib MJ, Khan MA. (2008). Stability indicating validated HPLC method for quantification of levothyroxine with eight degradation peaks in the presence of excipients. Int J Pharm, 360:77–82.
   PubMed Web of Science ®Google Scholar
• Sigfridsson K, Andersson T, Nilsson L, Schönbacher V, Wang Y. (2007). Pharmaceutical and analytical characterisation of (2R)-(3-amino-2-fluoropropyl)sulphinic acid, a GABAB receptor agonist. Eur J Pharm Biopharm, 65:104–110.
   PubMed Web of Science ®Google Scholar
• Yoshioka S, Stella VJ.. (2000). Stability of drugs and dosage forms. New York, NY: Kluwer Academic/Plenum Publishers.
   Google Scholar
• Hirsch CA, Messenger RJ, Brannon JL. (1978). Fenoprofen: Drug form selection and preformulation stability studies. J Pharm Sci, 67:231–236.
   PubMed Web of Science ®Google Scholar
• Engel GL, Farid NA, Faul MM, Richardson LA, Winneroski LL. (2000). Salt form selection and characterization of LY333531 mesylate monohydrate. Int J Pharm, 198:239–247.
   PubMed Web of Science ®Google Scholar
• Stahl PH, Wermuth CG>. (Eds.) (2002). Handbook of pharmaceutical salts, properties, selection and use. Weinheim, Germany: IUPAC, Wiley-VCH.
   Google Scholar
• Aakeröy CB, Fasulo ME, Desper J. (2007). Cocrystal or salt: Does it really matter? Mol Pharm, 4:317–322.
   PubMed Web of Science ®Google Scholar
• Schultheiss N, Newman A. (2009). Pharmaceutical Cocrystals and Their Physicochemical Properties. Cryst Growth Des, 9:2950–2967.
   PubMed Web of Science ®Google Scholar
• Brittain HG. (1999). Polymorphism in pharmaceutical solids. New York, NY: Marcel Dekker.
   Google Scholar
• Byrn SR, Pfeiffer RR, Stowell JG. (1999). Solid state chemistry of drugs, 2nd ed. West Lafayette, IN: SSCI Inc.
   Google Scholar
• Bernstein J. (2002). Polymorphism in molecular crystals. Oxford: Clarendon Press.
   Google Scholar
• Thirunahari S, Aitipamula S, Chow PS, Tan RB. (2010). Conformational polymorphism of tolbutamide: A structural, spectroscopic, and thermodynamic characterization of Burger*s forms I-IV. J Pharm Sci, 99:2975–2990.
   PubMedGoogle Scholar
• Sigfridsson K, Ahlqvist M, Lindsjö M, Paulsson S. (2011). Early development evaluation of AZD2738, a substrate for the NK receptors. Drug Dev Ind Pharm, 37:719–726.
   PubMed Web of Science ®Google Scholar
• Sigfridsson K, Ahlqvist M, Carlsson A, Fridström A. (2011). Early development evaluation of AZD8081: a substrate for the NK receptors. Drug Dev Ind Pharm, 37:702–713.
   PubMed Web of Science ®Google Scholar
• Sigfridsson K, Lundqvist R, Ohlson K. (2012). Preformulation evaluation of AZD1305, an oxabispidine intended for oral and intravenous treatment. Drug Dev Ind Pharm, 38:19–31.
   PubMed Web of Science ®Google Scholar
• Klinkenberg-Knol EC, Meuwissen SG. (1990). Combined gastric and oesophageal 24-hour pH monitoring and oesophageal manometry in patients with reflux disease, resistant to treatment with omeprazole. Aliment Pharmacol Ther, 4:485–495.
   PubMed Web of Science ®Google Scholar
• Holloway RH. (2000). The antireflux barrier and mechanisms of reflux. Best Pract Res, 14:681–701.
   Web of Science ®Google Scholar
• Vakil N. (2004). New pharmacological agents for the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Therap, 19:1041–1049.
   PubMed Web of Science ®Google Scholar
• Boeckxstaens GE, Beaumont H, Hatlebakk JG, Silberg DG, Björck K, Karlsson M et al.. (2011). A novel reflux inhibitor lesogaberan (AZD3355) as add-on treatment in patients with GORD with persistent reflux symptoms despite proton pump inhibitor therapy: A randomised placebo-controlled trial. Gut, 60:1182–1188.
   PubMed Web of Science ®Google Scholar
• Boeckxstaens GE, Beaumont H, Mertens V, Denison H, Ruth M, Adler J et al.. (2010). Effects f lesogaberan on reflux and lower esophageal sphincter function in patients with gastroesophageal reflux disease. Gastroenterology, 139:409–417.
   PubMed Web of Science ®Google Scholar
• Blackshaw LA, Staunton E, Lehmann A, Dent J. (1999). Inhibition of transient LES relaxations and reflux in ferrets by GABA receptor agonists. Am J Physiol, 277:G867–G874.
   PubMed Web of Science ®Google Scholar
• Lehmann A, Antonsson M, Bremner-Danielsen M, Fl*rdh M, Hansson-Br*nd*n L, K*rrberg L. (1999). Activation of the GABA(B) receptor inhibits transient lower esophageal sphincter relaxations in dogs. Gastroenterology, 117:1147–1154.
   PubMed Web of Science ®Google Scholar
• Lidums I, Lehmann A, Checklin H, Dent J, Holloway RH. (2000). Control of transient lower esophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in normal subjects. Gastroenterology, 118:7–13.
   PubMed Web of Science ®Google Scholar
• Liu J, Pehlivanov N, Mittal RK. (2002). Baclofen blocks LES relaxation and crural diaphragm inhibition by esophageal and gastric distension in cats. Am J Physiol Gastrointest Liver Physiol, 283:G1276–G1281.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Lehmann A, Rigda R, Dent J, Holloway RH. (2002). Control of transient lower oesophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in patients with gastro-oesophageal reflux disease. Gut, 50:19–24.
   PubMed Web of Science ®Google Scholar